CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
FG-3019 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02210559
NCT02210559Phase 2Completed
CompareCT.gov

A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer

Kyntra Bio·interventional·Posted Aug 6, 2014·Updated Mar 2, 2023

In Brief

A Phase 2 clinical trial evaluating FG-3019, Gemcitabine, and 1 other intervention for Pancreatic Cancer (Unresectable). Completed, enrolled 37 participants across 8 sites.

Detailed Summary

This is a Phase 1/2 trial to evaluate the safety, tolerability, and efficacy of FG-3019 administered with gemcitabine and nab-paclitaxel in the treatment of locally advanced, unresectable pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer (Unresectable)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 6, 2014
Enrollment StartJul 31, 2014
Primary CompletionDec 15, 2021
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 11.9 years ago

Interventions

FG-3019drug

FG-3019 will be administered per dose and schedule specified in the arm group description.

Gemcitabinedrug

Gemcitabine will be administered per dose and schedule specified in the arm group description.

Nab-paclitaxeldrug

Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.